lts around the world. The disease slowly destroys brain cells, leading to memory loss, confusion, personality changes, and difficulty performing everyday activities.
As the condition progresses, many people lose their independence and eventually require full-time care.
Today, millions of people are living with Alzheimer’s disease, and the number continues to rise as populations age. Despite decades of research, scientists have not yet found a cure. Current treatments can only help manage symptoms for a limited time and do not stop the disease from progressing.
In recent years, researchers have developed new drugs that target a protein called amyloid beta. This protein is believed to play a major role in Alzheimer’s disease because it can build up inside the brain and form sticky clumps known as plaques. These plaques are thought to damage brain cells and interfere with communication between neurons.
Although these new medications have generated excitement, they also come with challenges. Many are expensive, difficult to access, and may cause serious side effects in some patients. As a result, scientists continue searching for safer, more affordable treatments that could slow or prevent the disease.
A new study from researchers in Japan has revealed a promising possibility. Scientists have found that arginine, a naturally occurring amino acid that is already widely used as a dietary supplement, may help reduce harmful brain changes linked to Alzheimer’s disease.
The research was conducted by scientists from Kindai University and collaborating institutions and was published in the journal Neurochemistry International.
The study was led by graduate student Kanako Fujii, Professor Yoshitaka Nagai from the Department of Neurology at Kindai University, and Associate Professor Toshihide Takeuchi from the university’s Life Science Research Institute.
Arginine is a substance that occurs naturally in the human body and in many foods. It is found in meat, fish, dairy products, nuts, seeds, and legumes. The body uses arginine for many important functions, including supporting blood flow, wound healing, immune function, and the production of nitric oxide, a molecule that helps blood vessels relax.
Previous research had suggested that arginine might have additional benefits in the brain. The researchers wanted to investigate whether it could help prevent amyloid beta from forming harmful clumps.
To begin, the team conducted laboratory experiments using solutions containing amyloid beta proteins. They discovered that when arginine was added, the proteins became much less likely to stick together and form larger aggregates. The effect became stronger as the amount of arginine increased.
These results suggested that arginine acts as a type of molecular helper, interfering with the process that allows amyloid beta proteins to clump together.
The researchers then moved on to animal studies to see whether the same effects could occur in living organisms.
They used two widely accepted models of Alzheimer’s disease. One model involved genetically modified fruit flies that produced a particularly toxic form of amyloid beta.
The second involved special mice carrying three genetic mutations associated with Alzheimer’s disease in humans. These mice develop many of the brain abnormalities that are commonly seen in patients.
The results were encouraging.
In both the fruit flies and the mice, oral treatment with arginine reduced the accumulation of amyloid beta. In the mice, researchers observed significantly fewer amyloid plaques in the brain compared with untreated animals.
The treatment also lowered levels of an especially harmful form of amyloid beta known as insoluble Aβ42. This form of the protein is considered particularly dangerous because it is more likely to form plaques and contribute to brain damage.
Perhaps even more importantly, the mice treated with arginine performed better on tests designed to measure learning and memory. This suggests that the reduction in amyloid buildup may have translated into meaningful improvements in brain function.
The benefits extended beyond amyloid reduction.
Researchers also found lower levels of inflammatory molecules in the brains of treated mice. Inflammation is increasingly recognized as a major contributor to Alzheimer’s disease. When inflammation becomes chronic, it can worsen damage to nerve cells and accelerate the progression of the disease.
By reducing both amyloid accumulation and inflammation, arginine appeared to affect multiple processes involved in Alzheimer’s disease rather than targeting only one aspect of the condition.
Professor Nagai explained that one of the most attractive features of arginine is its long history of safe use in humans. Unlike many experimental drugs, arginine is already approved for medical use in Japan and has been studied extensively for other health conditions.
Another advantage is that arginine can enter the brain, allowing it to potentially act directly where the disease develops. Because scientists already know a great deal about its safety profile, moving toward human clinical trials may be faster than developing a completely new medication from scratch.
This strategy is known as drug repositioning. Instead of inventing a brand-new drug, researchers look for new uses for substances that are already known to be safe. Drug repositioning can reduce development costs, shorten timelines, and bring potential treatments to patients more quickly.
The researchers caution that people should not assume that over-the-counter arginine supplements will prevent or treat Alzheimer’s disease. The doses and treatment schedules used in the study were carefully controlled and are not directly comparable to commercial supplements.
In addition, animal studies do not always produce the same results in humans. Much more research is needed before doctors can recommend arginine as a treatment for Alzheimer’s disease.
Future studies will need to determine the most effective dose, how long treatment should continue, and whether the benefits seen in animals can be reproduced in people.
Even so, the findings are important because they demonstrate that a relatively simple and inexpensive compound can reduce key disease-related changes in animal models of Alzheimer’s disease.
Rather than promising a miracle cure, the research provides strong evidence that arginine deserves further investigation. It offers a realistic and scientifically grounded reason for optimism in a field where progress has often been slow and difficult.
If future human studies confirm these findings, arginine or related compounds could eventually become part of a new generation of more affordable treatments for Alzheimer’s disease. Such therapies could be particularly valuable in countries where access to expensive antibody treatments is limited.
For the millions of patients and families affected by Alzheimer’s disease, every new advance matters. While much work remains ahead, this study opens a promising new path and suggests that some future treatments may come from surprisingly simple substances that have been hiding in plain sight all along.
If you care about Alzheimer’s disease, please read studies about the protective power of dietary antioxidants against Alzheimer’s, and eating habits linked to higher Alzheimer’s risk.
For more health information, please see recent studies that oral cannabis extract may help reduce Alzheimer’s symptoms, and Vitamin E may help prevent Parkinson’s disease.
The study was published in Neurochemistry International.
Copyright © 2026 Knowridge Science Report. All rights reserved.
